Caption Management’s Neurocrine Biosciences NBIX Stock Holding History

Caption Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.95M	Buy	+30,000	New	+$3.98M	0.02%	602
2025 Q4	–	Sell	-53,000	Closed	-$7.44M	–	1917
2025 Q3	$7.44M	Buy	53,000 +13,000	+33%	+$1.76M	0.06%	362
2025 Q2	$5.03M	Sell	40,000 -110,300	-73%	-$12.6M	0.06%	408
2025 Q1	$16.6M	Buy	+150,300	New	+$19M	0.16%	115
2024 Q2	–	Sell	-25,000	Closed	-$3.45M	–	1391
2024 Q1	$3.45M	Sell	25,000 -29,900	-54%	-$4.08M	0.05%	389
2023 Q4	$7.23M	Buy	54,900 +22,400	+69%	+$2.58M	0.1%	249
2023 Q3	$3.66M	Buy	32,500 +2,500	+8%	+$263K	0.06%	408
2023 Q2	$2.83M	Hold	30,000	–	–	0.05%	417
2023 Q1	$3.04M	Buy	30,000 +10,000	+50%	+$1.04M	0.06%	343
2022 Q4	$2.39M	Buy	+20,000	New	+$2.34M	0.04%	512
2022 Q3	–	Sell	-55,000	Closed	-$5.36M	–	1733
2022 Q2	$5.36M	Sell	55,000 -85,000	-61%	-$7.85M	0.07%	327
2022 Q1	$13.1M	Buy	140,000 +80,000	+133%	+$6.78M	0.16%	153
2021 Q4	$5.11M	Sell	60,000 -30,000	-33%	-$2.76M	0.06%	451
2021 Q3	$8.63M	Buy	90,000 +30,000	+50%	+$2.83M	0.1%	268
2021 Q2	$5.84M	Buy	+60,000	New	+$5.75M	0.08%	336
2021 Q1	–	Sell	-80,000	Closed	-$7.67M	–	1277
2020 Q4	$7.67M	Buy	80,000 +11,000	+16%	+$1.06M	0.17%	157
2020 Q3	$6.64M	Buy	69,000 +39,000	+130%	+$4.51M	0.16%	159
2020 Q2	$3.66M	Hold	30,000	–	–	0.12%	227
2020 Q1	$2.6M	Buy	30,000 +5,000	+20%	+$489K	0.15%	192
2019 Q4	$2.69M	Buy	+25,000	New	+$2.62M	0.09%	306
2019 Q3	–	Sell	-30,000	Closed	-$2.53M	–	831
2019 Q2	$2.53M	Sell	30,000 -55,000	-65%	-$4.52M	0.13%	213
2019 Q1	$7.49M	Buy	+85,000	New	+$7.1M	0.41%	64

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caption Management's NBIX Position: Q1 2026 in Review

Caption Management opened a new position in Neurocrine Biosciences (NBIX) in Q1 2026: 8,900 shares worth $1.17M. The stake represents 0.01% of the portfolio and ranks #974 among its holdings. This is a return to the name: Caption Management previously reported a position in NBIX as recently as Q1 2025.

Caption Management first reported a position in NBIX in Q1 2019 and has held it in 17 quarters since. The position peaked at $14.5M in Q1 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Caption Management held 8,900 shares of Neurocrine Biosciences worth $1.17M as of Q1 2026.
Neurocrine Biosciences was a new Caption Management position in Q1 2026.
Neurocrine Biosciences made up 0.01% of Caption Management's portfolio in Q1 2026, its #974 holding.
Caption Management first reported a position in Neurocrine Biosciences in Q1 2019 and has held it in 17 quarters since.
Caption Management's Neurocrine Biosciences position peaked at $14.5M in Q1 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.